Efficacy and Safety of CS0159 Combined With Semaglutide in MASH Patients With Obesity and T2DM

NCT06492330 · Completed

Last updated 2026-05-28

This clinical trial is testing whether the combination of CS0159 and semaglutide can help reduce body weight in adults who have metabolic dysfunction-associated steatohepatitis (MASH), obesity, and type 2 diabetes.

Status Completed The study has finished.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 62 people

Who can join Ages 18–65 · all sexes

Timeline Started 2024-07 · est. completion 2025-04

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT06492330 ↗

Description as written by the study sponsor.

This is an exploratory study evaluating CS0159 in combination with Semaglutide in MASH patients with obesity and T2DM.

Treatments tested

CS0159 Drug

The intervention will include a 2-week screening period, a 16-week treatment period, and a 4-week follow-up period. Efficacy and safety evaluations will be conducted after the end of the treatment. During the 16-week treatment period, subjects will receive 4mg CS0159 (oral, once daily) + 0.5mg Semaglutide (subcutaneous injection, once weekly).
CS0159 placebo Drug

The intervention will include a 2-week screening period, a 16-week treatment period, and a 4-week follow-up period. Efficacy and safety evaluations will be conducted after the end of the treatment. During the 16-week treatment period, subjects will receive CS0159 placebo (oral, once daily) + 0.5mg Semaglutide (subcutaneous injection, once weekly).

Main thing measured	Percentage change in body weight relative to baseline
Sponsor	Shanghai Jiao Tong University School of Medicine
Conditions studied	Metabolic Dysfunction-Associated Steatohepatitis (MASH), Obesity, Diabetes Mellitus, Type 2
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06492330 ↗